Scientific Study Reveals New Weapon In Arthritis Battle
A new topical gel has been clinically proven to relieve pain and improve joint function associated with all stages of osteoarthritis, particularly for runners who are at higher risk of suffering wear and tear.
In a clinical trial on 1395 people with osteoarthritis of the knee, FLEXISEQ® gel was shown to reduce joint pain, stiffness and improve joint function.
The study found FLEXISEQ® gel achieved results equivalent to the effects of an oral, anti-inflammatory prescription drugi.
Arthritis is the major cause of disability and chronic pain in Australia, with 3.85million Australians affected at a cost to our economy of more than $23.9 billion each year in medical care and indirect costs such as loss of earnings and lost production i.
Current trends suggest that, by 2050, 7 million Australians will suffer from some form of arthritis.ii
FLEXISEQ® is a topical treatment that lubricates the cartilage in joints to relieve pain and stiffness.
Jonathan Freeman, Exercise Physiologist and Strength and Rehab Coach, said many studies have found that osteoarthritis begins with the injury that makes the joint unstableiii.
“The joint instability then increases the sliding between the joint surfaces and reduces the efficiency of the muscles. Disruption to the cartilage and underlying bone causes wear and increasing shear, which eventually leads to degeneration,” Freeman said.
FLEXISEQ® is a ‘smart’ gel, containing phospholipid spheres, called Sequessome™ vesicles that blend natural biology and technology to lubricate jointsii.
“These spheres, or bubbles, which are attracted to areas of high water content, are able to deform to penetrate through the skin and reach the target areas beneath”<span STYLE=”font-size: xx-small ! important”><span STYLE=”vertical-align:super;” >ii</span></span>.
“So in many respects these spheres act like a fluid-seeking missile to lubricate your joints” Dr Sam Yurdakul, Flexiseq Co-Creator and Director Product Development & Regulatory Affairs.
“People who used FLEXISEQ® gel twice daily achieved about 40 per cent reduction in pain associated with osteoarthritis” said Dr Yurdaku.
Clinical studies found that FLEXISEQ® gel also reduced joint stiffness and improved impaired joint function by more than 35 per cent, seen as early as just two days in some patients.ii.
“These results are similar to a commonly prescribed oral non-steroidal anti-inflammatory drug but without the systemic side effects often associated with those medications,” said Freeman.
Awarded the Innovation Award 2013 by the Federal Association of German Pharmacists, FLEXISEQ® gel is a unique topical therapy for quick and effective relief of joint pain associated with osteoarthritis.
An independent survey found 97 per cent of people with osteoarthritis judged FLEXISEQ® equal to or better than other products with respect to its effect on painiiii.
After just three weeks, 99 per cent of people said FLEXISEQ® had improved their joint mobility.
For further information visit www.flexiseq.com.au
I Reports – Painful realities: The economic impact of arthritis in Australia 2007 (REPORT BY ACCESS ECONOMICS PTY LIMITED FOR ARTHRITIS AUSTRALIA 31 JULY 2007).
II Conaghan P et al. Rheumatology 2013 Jul;52(7):1303-12.
IIII FLEXISEQ® ‘real life’ user trial from Feireabend.de – Post Marketing Study/Survey